237 related articles for article (PubMed ID: 27481952)
21. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Barriere SL
Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
[TBL] [Abstract][Full Text] [Related]
22. Consensus on Language for Advance Informed Consent in Health Care-Associated Pneumonia Clinical Trials Using a Delphi Process.
Corneli A; Calvert SB; Powers JH; Swezey T; Collyar D; Perry B; Farley JJ; Santiago J; Donnelly HK; De Anda C; Blanchard K; Fowler VG; Holland TL
JAMA Netw Open; 2020 May; 3(5):e205435. PubMed ID: 32442291
[TBL] [Abstract][Full Text] [Related]
23. Changes in the prevalence of pathogens causing hospital-acquired bacterial pneumonia and the impact of their antimicrobial resistance patterns on clinical outcomes: A propensity-score-matched study.
Choi MH; Kim D; Lee KH; Cho JH; Jeong SH
Int J Antimicrob Agents; 2023 Sep; 62(3):106886. PubMed ID: 37343808
[TBL] [Abstract][Full Text] [Related]
24. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
Lacy MK; Stryjewski ME; Wang W; Hardin TC; Nogid B; Luke DR; Shorr AF; Corey GR; Barriere SL
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S87-93. PubMed ID: 26316562
[TBL] [Abstract][Full Text] [Related]
25. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Gao W; Patel YT; Zhang Z; Johnson MG; Fiedler-Kelly J; Bruno CJ; Rhee EG; Anda C; Feng HP
J Clin Pharmacol; 2023 Mar; 63(3):352-357. PubMed ID: 36201105
[TBL] [Abstract][Full Text] [Related]
26. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design.
Niederman MS
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S12-7. PubMed ID: 20597660
[TBL] [Abstract][Full Text] [Related]
27. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective.
Laessig KA
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S117-9. PubMed ID: 20597659
[TBL] [Abstract][Full Text] [Related]
28. Workshop on clinical trials of antibacterial agents for hospital-acquired pneumonia and ventilator-associated pneumonia.
Bartlett JG; Barie PS; Niederman MS; Wunderink RG
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-3. PubMed ID: 20597654
[No Abstract] [Full Text] [Related]
29. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
; ; ; ; Spellberg B; Talbot G
Clin Infect Dis; 2010 Aug; 51 Suppl 1(Suppl 1):S150-70. PubMed ID: 20597666
[No Abstract] [Full Text] [Related]
30. Issues in the design of clinical trials for antibacterial drugs for hospital-acquired pneumonia and ventilator‐associated pneumonia. Proceedings of a workshop co-sponsored by the US Food and Drug Administration, Infectious Diseases Society of America, American College of Chest Physicians, American Thoracic Society, and Society of Critical Care Medicine. March 31-April 1 2009.
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-170. PubMed ID: 21058464
[No Abstract] [Full Text] [Related]
31. Review of recent clinical trials of hospital-acquired pneumonia and ventilator-associated pneumonia: a perspective from academia.
Kollef MH
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S29-35. PubMed ID: 20597668
[TBL] [Abstract][Full Text] [Related]
32. Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines.
File TM
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S42-7. PubMed ID: 20597671
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of adult patients in the intensive care unit with Pseudomonas aeruginosa pneumonia who received an active anti-pseudomonal β-lactam: Does "S" equal success in the presence of resistance to other anti-pseudomonal β-lactams?
Lodise TP; Puzniak LA; Chen LH; Tian Y; Wei R; Im TM; Tartof SY
Pharmacotherapy; 2021 Aug; 41(8):658-667. PubMed ID: 34097763
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial.
François B; Mercier E; Gonzalez C; Asehnoune K; Nseir S; Fiancette M; Desachy A; Plantefève G; Meziani F; de Lame PA; Laterre PF;
Intensive Care Med; 2018 Nov; 44(11):1787-1796. PubMed ID: 30343314
[TBL] [Abstract][Full Text] [Related]
35. The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012-2019.
Zilberberg MD; Nathanson BH; Puzniak LA; Dillon RJ; Shorr AF
BMC Infect Dis; 2022 Oct; 22(1):775. PubMed ID: 36199012
[TBL] [Abstract][Full Text] [Related]
36. Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies.
Wilson SE; Graham DR; Wang W; Bruss JB; Castaneda-Ruiz B
Infect Dis Ther; 2017 Sep; 6(3):413-422. PubMed ID: 28695347
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.
Flamm RK; Nichols WW; Sader HS; Farrell DJ; Jones RN
Int J Antimicrob Agents; 2016 Mar; 47(3):235-42. PubMed ID: 26920105
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!
Ambrose PG; Bhavnani SM; Ellis-Grosse EJ; Drusano GL
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S103-10. PubMed ID: 20597657
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia.
Patel M; Bellanti F; Daryani NM; Noormohamed N; Hilbert DW; Young K; Kulkarni P; Copalu W; Gheyas F; Rizk ML
Clin Transl Sci; 2022 Feb; 15(2):396-408. PubMed ID: 34704389
[TBL] [Abstract][Full Text] [Related]
40. Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014-2019.
Zilberberg MD; Nathanson BH; Puzniak LA; Shorr AF
Infect Control Hosp Epidemiol; 2022 Mar; 43(3):277-283. PubMed ID: 35322770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
